Literature DB >> 31959422

Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine.

Jordan A Stinson1, Carter R Palmer1, David P Miller1, Adrian B Li1, Kandice Lightner2, Heather Jost3, William C Weldon3, M Steven Oberste3, Jonathan A Kluge1, Kathryn M Kosuda4.   

Abstract

Current inactivated polio vaccine (IPV) products are sensitive to both freezing and elevated temperatures and therefore must be shipped and stored between 2 °C and 8 °C, a requirement that imposes financial and logistical challenges for global distribution. As such, there is a critical need for a robust, thermally stable IPV to support global polio eradication and post-eradication immunization needs. Here, we present the development of air-dried thin films for temperature stabilization of IPV using the biomaterial silk fibroin. Thin-film product compositions were optimized for physical properties as well as poliovirus D-antigen recovery and were tested under accelerated and real-time stability storage conditions. Silk fibroin IPV films maintained 70% D-antigen potency after storage for nearly three years at room temperature, and greater than 50% potency for IPV-2 and IPV-3 serotypes at 45 °C for one year. The immunogenicity of silk fibroin IPV films after 2-week storage at 45 °C was assessed in Wistar rats and the stressed films generated equivalent neutralizing antibody responses to commercial vaccine for IPV-1 and IPV-2. However, the absence of IPV-3 responses warrants further investigation into the specificity of ELISA for intact IPV-3 D-antigen. By demonstrating immunogenicity post-storage, we offer the air-dried silk film format as a means to increase IPV vaccine access through innovative delivery systems such as microneedles.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fibroin; Poliovirus; Silk; Stabilization; Vaccine

Mesh:

Substances:

Year:  2020        PMID: 31959422      PMCID: PMC7176408          DOI: 10.1016/j.vaccine.2019.12.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  The D-antigen content in poliovaccine as a measure of potency.

Authors:  A J BEALE
Journal:  Lancet       Date:  1961-11-25       Impact factor: 79.321

2.  Materials fabrication from Bombyx mori silk fibroin.

Authors:  Danielle N Rockwood; Rucsanda C Preda; Tuna Yücel; Xiaoqin Wang; Michael L Lovett; David L Kaplan
Journal:  Nat Protoc       Date:  2011-09-22       Impact factor: 13.491

Review 3.  Silk-based stabilization of biomacromolecules.

Authors:  Adrian B Li; Jonathan A Kluge; Nicholas A Guziewicz; Fiorenzo G Omenetto; David L Kaplan
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

4.  Stabilization and release of enzymes from silk films.

Authors:  Qiang Lu; Xiaoqin Wang; Xiao Hu; Peggy Cebe; Fiorenzo Omenetto; David L Kaplan
Journal:  Macromol Biosci       Date:  2010-04-08       Impact factor: 4.979

5.  Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life.

Authors:  G Kanra; T Silier; K Yurdakök; T Yavuz; S Baskan; B Ulukol; M Ceyhan; E Ozmert; F Türkay; T Pehlivan
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

6.  Standardized Methods for Detection of Poliovirus Antibodies.

Authors:  William C Weldon; M Steven Oberste; Mark A Pallansch
Journal:  Methods Mol Biol       Date:  2016

Review 7.  In vivo bioresponses to silk proteins.

Authors:  Amy E Thurber; Fiorenzo G Omenetto; David L Kaplan
Journal:  Biomaterials       Date:  2015-08-20       Impact factor: 12.479

8.  Water-insoluble silk films with silk I structure.

Authors:  Qiang Lu; Xiao Hu; Xiaoqin Wang; Jonathan A Kluge; Shenzhou Lu; Peggy Cebe; David L Kaplan
Journal:  Acta Biomater       Date:  2009-10-27       Impact factor: 8.947

9.  Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin.

Authors:  Simona Zipursky; Mamoudou Harouna Djingarey; Jean-Claude Lodjo; Laifoya Olodo; Sylvestre Tiendrebeogo; Olivier Ronveaux
Journal:  Vaccine       Date:  2014-02-19       Impact factor: 3.641

10.  High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses.

Authors:  David A Muller; Germain J P Fernando; Nick S Owens; Christiana Agyei-Yeboah; Jonathan C J Wei; Alexandra C I Depelsenaire; Angus Forster; Paul Fahey; William C Weldon; M Steven Oberste; Paul R Young; Mark A F Kendall
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

View more
  3 in total

1.  Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.

Authors:  Jordan A Stinson; Archana V Boopathy; Brian M Cieslewicz; Yichen Zhang; Nickolas W Hartman; David P Miller; Matthew Dirckx; Brett L Hurst; E Bart Tarbet; Jonathan A Kluge; Kathryn M Kosuda
Journal:  Vaccine       Date:  2021-08-12       Impact factor: 4.169

2.  Thermal stabilization of diverse biologics using reversible hydrogels.

Authors:  Bruno Marco-Dufort; John R Janczy; Tianjing Hu; Marco Lütolf; Francesco Gatti; Morris Wolf; Alex Woods; Stephan Tetter; Balaji V Sridhar; Mark W Tibbitt
Journal:  Sci Adv       Date:  2022-08-05       Impact factor: 14.957

Review 3.  Development of thermostable vaccine adjuvants.

Authors:  Yizhi Qi; Christopher B Fox
Journal:  Expert Rev Vaccines       Date:  2021-06-26       Impact factor: 5.683

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.